Indication

Prevention of recurrent vaso-occlusive crises (VOC) in sickle cell disease (SCD) patients aged 16 years and older, as either an add-on therapy to hydroxyurea/hydroxycarbamide (HC/HU) or as monotherapy in patients for whom HC/HU is inappropriate or inadequate.

Medicine details

Medicine name:
crizanlizumab (Adakveo)
SMC ID:
SMC2438
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Nutrition and blood
Submission type
Full
Publication due date:
11 July 2022
SMC meeting date:
07 June 2022
Patient group submission deadline:
04 April 2022